These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 35261333)

  • 1. Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease.
    Ferrucci S; Angileri L; Tavecchio S; Fumagalli S; Iurlo A; Cattaneo D; Marzano AV; Maronese CA
    J Dermatolog Treat; 2022 Aug; 33(5):2587-2592. PubMed ID: 35261333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
    Wechsler ME; Klion AD; Paggiaro P; Nair P; Staumont-Salle D; Radwan A; Johnson RR; Kapoor U; Khokhar FA; Daizadeh N; Chen Z; Laws E; Ortiz B; Jacob-Nara JA; Mannent LP; Rowe PJ; Deniz Y
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2695-2709. PubMed ID: 35636689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical significance of dupilumab-induced blood eosinophil elevation in Japanese patients with atopic dermatitis.
    Tosuji E; Inaba Y; Muraoka K; Kunimoto K; Kaminaka C; Yamamoto Y; Jinnin M
    Drug Discov Ther; 2022 Sep; 16(4):164-168. PubMed ID: 35989284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
    Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
    Br J Dermatol; 2020 May; 182(5):1120-1135. PubMed ID: 31407311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
    Nettis E; Ferrucci SM; Ortoncelli M; Pellacani G; Foti C; Di Leo E; Patruno C; Rongioletti F; Argenziano G; Macchia L; Tavecchio S; Napolitano M; Ribero S; Bonzano L; Romita P; Di Bona D; Nisticò SP; Piras V; Calabrese G; Detoraki C; Carbonara M; Fabbrocini G
    J Investig Allergol Clin Immunol; 2022 Apr; 32(2):124-132. PubMed ID: 32856595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review.
    Neagu N; Dianzani C; Avallone G; Dell'Aquila C; Morariu SH; Zalaudek I; Conforti C
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):820-835. PubMed ID: 35122335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facial and neck erythema associated with dupilumab treatment: A systematic review.
    Jo CE; Finstad A; Georgakopoulos JR; Piguet V; Yeung J; Drucker AM
    J Am Acad Dermatol; 2021 May; 84(5):1339-1347. PubMed ID: 33428978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: a bicentric retrospective comparative cohort study.
    Barbé J; Poreaux C; Remen T; Schoeffler A; Cloché V; Schmutz JL; Escobar G; Busztejn AC
    Int J Dermatol; 2021 Dec; 60(12):1520-1528. PubMed ID: 34037253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Treister AD; Kraff-Cooper C; Lio PA
    JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: An Italian single-center experience.
    Napolitano M; Di Guida A; Fabbrocini G; Patruno C
    Dermatol Ther; 2021 Sep; 34(5):e15059. PubMed ID: 34241938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facial erythema in patients with atopic dermatitis treated with Dupilumab - a descriptive study of morphology and Aetiology.
    Ahn J; Lee DH; Na CH; Shim DH; Choi YS; Jung HJ; Simpson EL
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2140-2152. PubMed ID: 35695074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term real-world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6 years and above: Retrospective chart analysis from a single tertiary care center.
    Parmar NV; Abdula MA; Al Falasi A; Krishna CV
    Dermatol Ther; 2022 May; 35(5):e15415. PubMed ID: 35238115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular Surface Disease in Patients With Atopic Dermatitis Treated With Dupilumab: A Prospective Case-Control Study.
    Marolo P; Ribero S; Caselgrandi P; Ghilardi A; de Sanctis U; Parisi G; Fallico M; Borrelli E; Ortoncelli M; Gelato F; Mastorino L; Tibaldi T; Roccuzzo G; Quaglino P; Reibaldi M
    Cornea; 2024 Feb; 43(2):221-227. PubMed ID: 37404010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of dupilumab for the treatment of atopic dermatitis among Chinese patients in clinical practice: A single-center retrospective study.
    Li Y; Lu J; Chen R; Wang Y; Ding Y; Xu S; Zou Y; Yi X; Shi Y
    Dermatol Ther; 2022 May; 35(5):e15385. PubMed ID: 35174593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis.
    Achten R; Thijs J; van der Wal M; van Luijk C; de Graaf M; Bakker D; de Boer J; van Wijk F; de Bruin-Weller M
    Allergy; 2023 Aug; 78(8):2266-2276. PubMed ID: 36934403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
    Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
    J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.